With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Lower muscle volume, and more fat stored in the muscle, are seen linked to higher risk for disease and comorbidities.

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some ...

Did you know that arthritis can also affect children, and not just their joints? Juvenile arthritis is more than just joint ...

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

Both men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)—a chronic inflammatory ...

IL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily ...

Patients with psoriatic arthritis with a family history of psoriatic disease are diagnosed with psoriasis and psoriatic ...

Early intervention in psoriatic arthritis (PsA) is disease-modifying, and delays in diagnosis, even by 6 months, can reduce ...